{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:41:37Z","timestamp":1794534097376,"version":"4.9.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2019\/SKK08\/SYUC\/03\/2"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK08\/SYUC\/03\/2"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009388","name":"Jazan University","doi-asserted-by":"publisher","award":["RG24-L01"],"award-info":[{"award-number":["RG24-L01"]}],"id":[{"id":"10.13039\/100009388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33052","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:55:15Z","timestamp":1718715315000},"page":"e33052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat"],"prefix":"10.1016","volume":"10","author":[{"given":"Nasreddine","family":"El Omari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaad","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz A.","family":"Makeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A.","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Albratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syam","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching Siang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Bee","family":"Chook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Bouyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e33052_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/cells11030552","article-title":"Oxidative stress in human pathology and aging: molecular mechanisms and perspectives","volume":"11","author":"Hajam","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e33052_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00080","article-title":"DNA methyltransferases: a novel target for prevention and therapy","volume":"4","author":"Subramaniam","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13205-020-02473-1","article-title":"Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways","volume":"10","author":"Kedhari Sundaram","year":"2020","journal-title":"3 Biotech"},{"key":"10.1016\/j.heliyon.2024.e33052_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-12937-4","article-title":"Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice","volume":"12","author":"Al-Griw","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e33052_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.heliyon.2024.e33052_bib6","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/molecules27082568","article-title":"Natural bioactive compounds targeting histone deacetylases in human cancers: recent updates","volume":"27","author":"Bouyahya","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e33052_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120321","article-title":"Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: epigenetic mnemonics","author":"Mandumpala","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib8","series-title":"Semin. Cancer Biol.","first-page":"452","article-title":"Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress","author":"Neganova","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e33052_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33052_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","author":"Hai","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/cells11020223","article-title":"Analysis of 5-azacytidine resistance models reveals a set of targetable pathways","volume":"11","author":"Mina\u0159\u00edk","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e33052_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.semcancer.2021.06.023","article-title":"Role of epigenetics in carcinogenesis: recent advancements in anticancer therapy","volume":"83","author":"Hussain","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib13","doi-asserted-by":"crossref","unstructured":"S. Tasneem, M.M. Alam, M. Amir, M. Akhter, S. Parvez, G. Verma, L.M. Nainwal, A. Equbal, T. Anwer, M. Shaquiquzzaman, Heterocyclic moieties as HDAC inhibitors: role in cancer therapeutics, Mini-Rev. Med. Chem. 22 (n.d.) 1648\u20131706.","DOI":"10.2174\/1389557519666211221144013"},{"key":"10.1016\/j.heliyon.2024.e33052_bib14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","article-title":"Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of \u03b3-H2AX foci","volume":"5","author":"Munshi","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e33052_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1535-7163.MCT-08-0534","article-title":"Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models","volume":"8","author":"Pitts","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e33052_bib16","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","article-title":"Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis","volume":"8","author":"Bruzzese","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e33052_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.heliyon.2024.e33052_bib18","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.3390\/nu13113714","article-title":"Natural bioactive compounds targeting epigenetic pathways in cancer: a review on alkaloids, terpenoids, quinones, and isothiocyanates","volume":"13","author":"El Omari","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2024.e33052_bib19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.heliyon.2024.e33052_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e33052_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2024.e33052_bib22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e33052_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/17460441.2017.1295954","article-title":"Exploring the epigenetic drug discovery landscape","volume":"12","author":"Prachayasittikul","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e33052_bib24","article-title":"Histone modifications, rev","volume":"1-16","author":"Xhemalce","year":"2006","journal-title":"Cell Biol. Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e33052_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","article-title":"Functions and mechanisms of non-histone protein acetylation","volume":"20","author":"Narita","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/jmbi.2001.4859","article-title":"Structure of histone acetyltransferases","volume":"311","author":"Marmorstein","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e33052_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2010.02.010","article-title":"Histone deacetylases and epigenetic therapies of hematological malignancies","volume":"62","author":"Mercurio","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.heliyon.2024.e33052_bib31","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e33052_bib32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","article-title":"Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast","volume":"94","author":"Zhang","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e33052_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","article-title":"Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis","volume":"5","author":"Zhu","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e33052_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21 Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.heliyon.2024.e33052_bib36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"Apmis"},{"key":"10.1016\/j.heliyon.2024.e33052_bib37","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2024.e33052_bib39","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-07-0312","article-title":"Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice","volume":"67","author":"Zimmermann","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib40","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1042\/BCJ20180465","article-title":"HDAC1 overexpression enhances \u03b2-cell proliferation by down-regulating Cdkn1b\/p27","volume":"475","author":"Draney","year":"2018","journal-title":"Biochem. J."},{"key":"10.1016\/j.heliyon.2024.e33052_bib41","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/molecules27082568","article-title":"Natural bioactive compounds targeting histone deacetylases in human cancers: recent updates","volume":"27","author":"Bouyahya","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e33052_bib42","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.22558","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells","volume":"121","author":"Kumagai","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib43","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4161\/cbt.8.9.8118","article-title":"Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed","volume":"8","author":"Di Gennaro","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.heliyon.2024.e33052_bib44","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","article-title":"Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase","volume":"103","author":"Di Gennaro","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib45","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT","volume":"226","author":"Bruzzese","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib46","first-page":"1","article-title":"Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells","volume":"2013","author":"Kwak","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.heliyon.2024.e33052_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12951-015-0122-4","article-title":"Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells","volume":"13","author":"Kwak","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0609.2009.01384.x","article-title":"Vorinostat enhances the antimyeloma effects of melphalan and bortezomib","volume":"84","author":"Campbell","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib49","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-09-3174","article-title":"Synergistic killing effect between vorinostat and target of CD146 in malignant cells","volume":"16","author":"Ma","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib50","series-title":"Histone Deacetylase Inhibitor Vorinostat Suppresses the Growth of Uterine Sarcomas in Vitro and in Vivo","author":"Hrzenjak","year":"2010"},{"key":"10.1016\/j.heliyon.2024.e33052_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1593\/neo.91422","article-title":"Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat","volume":"12","author":"Kahali","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.heliyon.2024.e33052_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","article-title":"Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms","volume":"306","author":"Mueller","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2024.e33052_bib54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/cgt.2011.11","article-title":"Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells","volume":"18","author":"Kim","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e33052_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024468","article-title":"The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway","volume":"6","author":"Sarfstein","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib56","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib57","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3892\/ijo.2012.1551","article-title":"SAHA\/Vorinostat induces the expression of the CD137 receptor\/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line","volume":"41","author":"Bellarosa","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2407-12-145","article-title":"Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells","volume":"12","author":"Phillip","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.taap.2012.11.002","article-title":"Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model","volume":"266","author":"Kurundkar","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molonc.2013.03.003","article-title":"Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells","volume":"7","author":"Bergad\u00e0","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.expneurol.2012.12.006","article-title":"Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis","volume":"241","author":"Ge","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10637-012-9831-9","article-title":"Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines","volume":"31","author":"Muscal","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e33052_bib63","first-page":"1770","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.heliyon.2024.e33052_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074525","article-title":"Reactivation of estrogen receptor \u03b1 by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor","volume":"8","author":"Stark","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/carcin\/bgs319","article-title":"The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer","volume":"34","author":"Tran","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.heliyon.2024.e33052_bib66","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10637-012-9914-7","article-title":"Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer","volume":"31","author":"Wilson","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e33052_bib67","article-title":"Evaluation of the antitumor effects of bpr1j-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106224","article-title":"The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition","volume":"9","author":"Hutt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2015.06.145","article-title":"The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells","volume":"464","author":"Lu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e33052_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/10428194.2015.1063143","article-title":"Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells, Leuk","volume":"57","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e33052_bib71","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-016-2888-7","article-title":"Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells","volume":"16","author":"Pan","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","article-title":"Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents","volume":"142","author":"Xue","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib73","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1208\/s12249-018-1149-2","article-title":"Evaluation of anti-tumor efficacy of vorinostat encapsulated self-assembled polymeric micelles in solid tumors","volume":"19","author":"Rompicharla","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.heliyon.2024.e33052_bib74","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bmc.2019.02.046","article-title":"Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro","volume":"27","author":"Liu","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e33052_bib75","doi-asserted-by":"crossref","DOI":"10.3892\/or.2018.6814","article-title":"Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation","author":"Park","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e33052_bib76","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-18-1117","article-title":"Vorinostat potentiates 5-fluorouracil\/cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing cisplatin uptake","volume":"18","author":"Piro","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e33052_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218382","article-title":"Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells","volume":"14","author":"Eto","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000195","article-title":"Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis","volume":"8","author":"Laengle","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib79","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1039\/D0BM01516D","article-title":"Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment","volume":"8","author":"Tu","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173057","article-title":"Vorinostat upregulates MICA via the PI3K\/Akt pathway to enhance the ability of natural killer cells to kill tumor cells","volume":"875","author":"Xia","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib81","article-title":"Abstract 4898: imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles","author":"Zhang","year":"2023","journal-title":"Cancer Research | American Association for Cancer Research (2023)"},{"key":"10.1016\/j.heliyon.2024.e33052_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbcan.2012.02.001","article-title":"Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks","volume":"1826","author":"Li","year":"2012","journal-title":"Biochim. Biophys. Acta BBA - Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib83","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.heliyon.2024.e33052_bib84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.21147\/j.issn.1000-9604.2018.02.01","article-title":"Future of anti-PD-1\/PD-L1 applications: combinations with other therapeutic regimens","volume":"30","author":"Song","year":"2018","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib86","first-page":"1","article-title":"The intracellular signalosome of PD-L1 in cancer cells, Signal Transduct. Target","volume":"3","author":"Escors","year":"2018","journal-title":"Ther."},{"key":"10.1016\/j.heliyon.2024.e33052_bib87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/cancers12040777","article-title":"Development of prostate cancer organoid culture models in basic medicine and translational research","volume":"12","author":"Elbadawy","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33052_bib88","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/me.2012-1056","article-title":"Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer","volume":"26","author":"Reebye","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib89","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cells8060532","article-title":"HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy","volume":"8","author":"Condelli","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e33052_bib90","doi-asserted-by":"crossref","DOI":"10.1124\/mol.116.103416","article-title":"Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease HSP90 and the androgen receptor levels and inhibit viability in enzalutamide resistant C4-2 prostate cancer cells","author":"Rosati","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib91","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.3390\/cancers14225520","article-title":"Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy","volume":"14","author":"Bouyahya","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33052_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc2129","article-title":"Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer","volume":"7","author":"Liby","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib93","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1124\/pr.111.004846","article-title":"Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease","volume":"64","author":"Liby","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.heliyon.2024.e33052_bib94","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/S0960-894X(98)00479-X","article-title":"Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages","volume":"8","author":"Honda","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.heliyon.2024.e33052_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108520","article-title":"Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome","volume":"9","author":"Oua\u00efssi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33052_bib96","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.24479","article-title":"Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH","volume":"83","author":"Chang","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.heliyon.2024.e33052_bib97","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.3390\/cimb45070375","article-title":"The synergistic antitumor effect of decitabine and vorinostat combination on HepG2 human hepatocellular carcinoma cell line via epigenetic modulation of autophagy\u2013apoptosis molecular crosstalk","volume":"45","author":"Salama","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.31557\/APJCP.2021.22.S1.33","article-title":"Cytotoxicity of simvastatin in human breast cancer MCF-7 and MDA-MB-231 cell lines","volume":"22","author":"Rezano","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.heliyon.2024.e33052_bib99","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1124\/mol.62.5.1154","article-title":"The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae","volume":"62","author":"Lin","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174399","article-title":"Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway","volume":"908","author":"Pan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/cancers12010109","article-title":"Molecular determinants of cancer therapy resistance to HDAC inhibitor-induced autophagy","volume":"12","author":"Mrakovcic","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33052_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.144740","article-title":"Codelivery of vorinostat and chloroquine by autophagy-inhibitory hollow ZrO2 nanoshells for synergistic combination chemotherapy","volume":"471","author":"Chen","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.heliyon.2024.e33052_bib103","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.3390\/ijms24098075","article-title":"Differential response of mycosis fungoides cells to vorinostat","volume":"24","author":"Bordeaux","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib104","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1134\/S000629792307009X","article-title":"Histone methyltransferases as a new target for epigenetic action of vorinostat","volume":"88","author":"Maksimova","year":"2023","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.heliyon.2024.e33052_bib106","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","article-title":"Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies","volume":"13","author":"Ramalingam","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib109","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.18044","article-title":"A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC)","volume":"25","author":"Traynor","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","article-title":"Phase II trial of the histone deacetylase inhibitor vorinostat (ZolinzaTM, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer","volume":"26","author":"Blumenschein","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e33052_bib111","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib112","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1349-7006.2009.01237.x","article-title":"Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors","volume":"100","author":"Fujiwara","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib113","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/jc.2008-1631","article-title":"Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma","volume":"94","author":"Woyach","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e33052_bib114","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","article-title":"Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study","volume":"11","author":"Ree","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib115","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","article-title":"Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin\u2019s lymphomas","volume":"17","author":"Stathis","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib116","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib117","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e33052_bib118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-011-1762-1","article-title":"A randomized phase II study of two doses of vorinostat in combination with 5-FU\/LV in patients with refractory colorectal cancer","volume":"69","author":"Fakih","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib119","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination","volume":"30","author":"Millward","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e33052_bib120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0032-1323692","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia, klin","volume":"224","author":"Witt","year":"2012","journal-title":"P\u00e4diatr"},{"key":"10.1016\/j.heliyon.2024.e33052_bib121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10147-011-0348-6","article-title":"Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial","volume":"18","author":"Doi","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-014-3008-5","article-title":"A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer","volume":"146","author":"Tu","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e33052_bib123","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/auto.29231","article-title":"Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors","volume":"10","author":"Mahalingam","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.heliyon.2024.e33052_bib124","doi-asserted-by":"crossref","first-page":"59087","DOI":"10.18632\/oncotarget.10824","article-title":"Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer","volume":"7","author":"Patel","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e33052_bib125","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/bjc.2017.33","article-title":"Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I\/II clinical trial","volume":"116","author":"Pili","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17476348.2020.1701439","article-title":"Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations","volume":"14","author":"Reck","year":"2020","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.heliyon.2024.e33052_bib126","series-title":"Role of Pharmacokinetics in Safety Evaluation and Regulatory Considerations","author":"Scheuplein","year":"1990"},{"key":"10.1016\/j.heliyon.2024.e33052_bib127","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/ERC-19-0491","article-title":"Redifferentiation of radioiodine-refractory thyroid cancers","volume":"27","author":"Buffet","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.03.012","article-title":"Radioiodine refractory differentiated thyroid cancer","volume":"125","author":"Jin","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2015.05.021","article-title":"Palliative pelvic radiotherapy for symptomatic incurable prostate cancer \u2013 a prospective multicenter study","volume":"115","author":"Cameron","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33052_bib130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12298-018-0605-5","article-title":"Effect of elicitors on the metabolites in the suspension cell culture of Salvia miltiorrhiza Bunge","volume":"25","author":"Yu","year":"2019","journal-title":"Physiol. Mol. Biol. Plants"},{"key":"10.1016\/j.heliyon.2024.e33052_bib131","doi-asserted-by":"crossref","first-page":"326","DOI":"10.31083\/j.fbl2712326","article-title":"DNA methylation: from cancer biology to clinical perspectives","volume":"27","author":"Chen","year":"2022","journal-title":"Front. Biosci.-Landmark"},{"key":"10.1016\/j.heliyon.2024.e33052_bib132","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/biology11081225","article-title":"The effects of tamoxifen on tolerogenic cells in cancer","volume":"11","author":"Mohd Idris","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.heliyon.2024.e33052_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212371","volume":"22","author":"Jurutka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib134","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20041470","article-title":"A role for IgG immune complexes during infection with the intracellular pathogen Leishmania","volume":"201","author":"Miles","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e33052_bib135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.heliyon.2024.e33052_bib136","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e33052_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118745","article-title":"Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy","volume":"265","author":"Zamame Ramirez","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib138","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-020-01039-5","article-title":"Autophagy as a therapeutic target in pancreatic cancer","volume":"124","author":"Piffoux","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib139","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12943-019-0944-z","article-title":"The relationship between autophagy and the immune system and its applications for tumor immunotherapy","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2024.e33052_bib140","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1158\/0008-5472.CAN-12-2236","article-title":"Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy","volume":"72","author":"Ramakrishnan","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33052_bib141","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161206775201910","article-title":"VEGF inhibitors in cancer therapy","volume":"12","author":"Cardones","year":"2006","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e33052_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","article-title":"VEGF as a therapeutic target in cancer","volume":"69","author":"Ferrara","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.heliyon.2024.e33052_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114886","article-title":"Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e33052_bib144","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/ph15101235","article-title":"Pharmacological properties of trichostatin A, focusing on the anticancer potential: a comprehensive review","volume":"15","author":"Bouyahya","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2024.e33052_bib145","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/biom11121803","article-title":"Health benefits and pharmacological properties of carvone","volume":"11","author":"Bouyahya","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.heliyon.2024.e33052_bib146","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/separations8110207","article-title":"Anticancer and anti-inflammatory effects of tomentosin: cellular and molecular mechanisms","volume":"8","author":"El Omari","year":"2021","journal-title":"Separations"},{"key":"10.1016\/j.heliyon.2024.e33052_bib147","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12935-020-1100-y","article-title":"Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis","volume":"20","author":"Khorsandi","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.heliyon.2024.e33052_bib148","article-title":"Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non-small cell lung cancer A549 cells via the JAK\/STAT3 signaling pathway, Oncol","author":"Zhang","year":"2019","journal-title":"Rep"},{"key":"10.1016\/j.heliyon.2024.e33052_bib149","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13578-020-00397-0","article-title":"Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells","volume":"10","author":"Vafadar","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.heliyon.2024.e33052_bib150","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3390\/ijms20133177","article-title":"The anti-cancer effect of quercetin: molecular implications in cancer metabolism","volume":"20","author":"Reyes-Farias","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:10:18Z","timestamp":1790543418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024090832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":150,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024090832"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33052","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33052"}}